PerkinElmer and Predictive Diagnostics Announce Discovery of Blood Biomarkers for Alzheimer's Disease

21 April 2005

PerkinElmer Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc. (PDI), a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced today that they have found a series of biomarkers that appear to differ in persons with Alzheimer's Disease compared to persons without cognitive impairment, using a simple blood test.

The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center (Chicago, Illinois), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study. Mary Lopez, Ph.D., Business Leader for Analytical Proteomics at PerkinElmer presented the results on Thursday, April 14, 2005, at AACC's Oak Ridge Conference in Baltimore, Maryland. The blood analysis was carried out using PerkinElmer's BioXPRESSION™ Biomarker platform and Predictive Diagnostic's proprietary BAMF™ technology to identify patterns of proteins and peptides that distinguish Alzheimer's disease patients from those without clinical signs. The serum samples used in the study were donated by the Rush University Medical Center.

PerkinElmer's state-of-the-art BioXPRESSION™ Biomarker discovery and screening platform includes the novel prOTOF 2000™ MALDI mass spectrometer, ProXPRESSION™ carrier protein-based blood biomarker enrichment kits and PDI's BAMF™ technology.

"This study demonstrates the power of our comprehensive suite of tools and technologies for biomarker discovery and analysis," said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "We believe the detection of early disease-related biomarkers is crucial to facilitate the development of diagnostics and drug therapies."

In numerous collaborative studies, Predictive Diagnostics has demonstrated the capability of its BAMF™ technology to accurately diagnose cancers such as breast, lung, pancreatic and prostate, as well as multiple sclerosis. Predictive Diagnostics believes its diagnostic tests will provide better patient outcome through early detection of cancer and other serious diseases and significantly reduce the cost of healthcare associated with treatment of such diseases.

Further information about Predictive Diagnostics, Inc. can be found on the company's website (www.predictivediagnostics.com).

About PerkinElmer

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

About Large Scale Biology Corporation

Large Scale Biology Corporation is a biotechnology company developing and biomanufacturing biotherapeutics, diagnostic tests, vaccines and industrial proteins for important life science industry markets. Corporate headquarters, molecular biology and product design laboratories, and Predictive Diagnostics, Inc., are located in Vacaville, California, and the Company's bioprocess development and commercial-scale biomanufacturing facilities are located in Owensboro, Kentucky. In addition to its class-leading internal capabilities, LSBC relies on a network of industry, government and academic collaborators throughout the US and Europe to achieve rapid, commercially relevant product discovery, optimization and manufacturing. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.

Source: MARKET WIRE

All trademarks and copyrighted information contained herein are the property of their respective owners.